What does Exenatide do? Benefits and evidence

An older GLP-1 with twice-daily and weekly forms, now widely discontinued.

Also called: Byetta, Bydureon, Bydureon BCise, exendin-4, AC2993, ITCA 650.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

Exenatide is a GLP-1 medicine first approved for type 2 diabetes in 2005. Twice-daily and weekly products have different dosing and kidney limits. Many branded products are now withdrawn or discontinued. Trials support glucose lowering, but EXSCEL did not prove fewer major heart events. Stomach upset, dehydration and kidney injury are key risks.

  • Exenatide is approved for type 2 diabetes in adults, though some brand-name versions have since been withdrawn. (Drug label)
  • In a trial, the weekly form lowered the long-term blood sugar score by 1.9 points, versus 1.5 for the twice-daily form. (Studied in a trial)
  • In diabetes trials, people also lost some weight, but it is not approved for weight loss. (Studied in a trial)

Uses in the sources

  • Immediate-release exenatide has an adult type 2 diabetes label; weekly labels also included ages 10 and older. Approval is separate from current supply. (Drug label) (source)
  • Weight reduction occurred in diabetes trials; exenatide has no US weight-management indication. (Studied in a trial) (source)
  • The 2025 phase 3 Parkinson's trial found no slowing of motor decline over 96 weeks. (Studied in a trial) (source)

Related to Exenatide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.